Rubedo Life Sciences gets FDA IND clearance for lead drug RLS-1496 in actinic keratosis

Rubedo Life Sciences has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for RLS-1496 to begin a Phase 1b/2a clinical trial in patients with actinic keratosis, according to the company. RLS-1496 is a first-in-class, selective glutathione peroxidase 4 (GPX4) modulator being developed to target pathological senescent […] The post Rubedo Life Sciences gets FDA IND clearance for lead drug RLS-1496 in actinic keratosis appeared first on Longevity.Technology.